0001690585 2026-09-17 2026-09-17 0001690585 1 2026-09-17 2026-09-17 0001690585 2 2026-09-17 2026-09-17 0001690585 3 2026-09-17 2026-09-17 0001690585 4 2026-09-17 2026-09-17 0001690585 5 2026-09-17 2026-09-17 0001690585 6 2026-09-17 2026-09-17 iso4217:USD pure S-3 S-3ASR EX-FILING FEES 0001690585 Dianthus Therapeutics, Inc. /DE/ N/A N/A S-3 Dianthus Therapeutics, Inc. /DE/ false Equity Common stock, $0.001 par value per share true 0.0001381 false Equity Preferred stock, $0.001 par value per share true 0.0001381 false Debt Debt Securities true 0.0001381 false Other Warrants true 0.0001381 false Other Units true 0.0001381 false Equity Common stock, $0.001 par value per share true 500000000.00 0.0001381 69050.00 500000000.00 69050.00 0.00 0.00 69050.00 An indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units is being registered hereunder. There is also being registered hereunder such currently indeterminate number of (i) shares of common stock or other securities of the registrant as may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) shares of preferred stock, common stock, debt securities or units as may be issued upon exercise of warrants registered hereby, as the case may be. Any securities registered hereunder may be sold separately or as units with the other securities registered hereunder. The proposed maximum aggregate offering price per unit will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act of 1933, as amended (the "Securities Act"). No separate consideration will be received for (i) common stock or other securities of the registrant that may be issued upon conversion of, or in exchange for, convertible or exchangeable debt securities and/or preferred stock registered hereby, or (ii) preferred stock, common stock, debt securities or units that may be issued upon exercise of warrants registered hereby, as the case may be. See Note 1. See Note 1. See Note 1. See Note 1. In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of the filing fees relating to the securities that are registered and available for sale under this registration statement other than the fees in connection with the $500,000,000 of the registrant's common stock that may be issued and sold from time to time under the Sales Agreement, dated September 18, 2026, with TD Securities (USA) LLC, as sales agent.